Replacing a crystal ball with a calculator in predicting liver disease outcomes  by Friedman, Scott L.
FocusReplacing a crystal ball with a calculator in predicting liver
disease outcomes
Scott L. Friedman⇑
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, United States
See Articles, pages 934–939 and pages 948–954There is growing optimism about the potential to stabilize or
reverse advanced liver disease thanks to remarkable progress in
the treatment of chronic viral hepatitis. Striking evidence of cir-
rhosis reversibility in patients treated with antiviral therapies
for HBV [1] or HCV [2] raises the prospect of exploiting pathways
of ﬁbrosis regression to treat other chronic liver diseases, in par-
ticular alcoholic and non-alcoholic fatty liver diseases. In these
latter illnesses, however, one must rely on evidence of improve-
ment in either histology or other indices of liver structure or
function, rather than the more straightforward prospect of mea-
suring viral suppression as a determinant of improvement. It’s
worth noting that initially in early antiviral trials, regulatory
agencies still required evidence of histologic improvement in
association with viral suppression before relying solely on viral
endpoints as an index of efﬁcacy.
It is also important to remember that improved histology
alone does not guarantee improved outcomes, and the goal of
any effective therapy is to enhance health and/or survival, not
to improve a biopsy score. In that spirit there is intensiﬁed inter-
est in identifying measures that can accurately predict clinical
outcomes, whether they require invasive (i.e., biopsy) or non-
invasive assessment. In fact, there has been scant evidence to
date that standard liver biopsy staging systems correlate rigor-
ously with outcomes, in part because traditional scoring systems
rely on semi-quantitative staging rather than exact quantiﬁcation
of ﬁbrosis content.
Two complementary studies in this month’s issue of the Jour-
nal address these key questions, the ﬁrst by Tsochatzis et al.,
which uses a quantitative measure of collagen content in liver
biopsies to establish a correlation with clinical outcomes, and
the second by Asrani et al., which exploits the emerging technol-
ogy of magnetic resonance elastography to correlate liver stiff-
ness with the risk of decompensation.
The study by Tsochatzis and colleagues from the Royal Free
Hospital/University College London builds upon their previously
described method of collagen proportionate area, or CPA, whichJournal of Hepatology 20
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E-mail address: scott.friedman@mssm.eduquantiﬁes collagen content in liver biopsy specimens, rather than
relying solely on semi-quantitative scoring systems [3]. In this
new study, however, the investigators have directly compared
the accuracy of this method with the scoring systems of either
Laennec [4], Kumar [5] or Nagula [6] in the same patient cohort
to determine their relative value in predicting outcomes among
69 patients who were followed for a mean of 65 months follow-
ing biopsy. The CPA requires staining of liver biopsy specimens
with sirius red, followed by digital morphometric quantiﬁcation
of stained tissue, expressed as a percentage of total area [3]. In
addition to specialized software with a one-time cost of 7800
Euros, the CPA requires an additional 10 min per sample of the
pathologist’s (or technician’s) time to gather data. In this study,
a number of histologic variables were quantiﬁed, including septal
thickness, nodule size, as well as ﬁbrosis stage for each of the
scoring systems, yet CPA was the only biopsy variable indepen-
dently associated with clinical decompensation, and was compa-
rable to MELD in this respect. These data reinforce the value of
quantitative assessment of collagen content as a more accurate
determinant of prognosis than standard staging systems. Inter-
estingly, this kind of digital assessment is routinely used in ani-
mal models that test anti-ﬁbrotic drugs, yet clinical
pathologists have been slow to embrace the technology.
Of course, the obvious criticism is that CPA, while more accu-
rate than standard staging systems, still requires invasive liver
biopsy via either the trans-jugular or percutaneous route, and,
moreover, that the tissue specimen must be sufﬁciently large to
minimize sampling variability. Furthermore, many patients with
apparent cirrhosis by clinical and or imaging assessment are unli-
kely to undergo biopsy if the etiology is already known, and one
could not justify performing a liver biopsy simply to predict prog-
nosis by CPA, particularly if the MELD is already abnormal, since
MELD correlates perfectly well with outcomes. Still, the method
reinforces the importance of quantitative collagen content in
determining risk of decompensation, as reported by others as
well [7]. Because collagen continues to accumulate even when
the biopsy stage is ‘cirrhosis’ [8], this and related morphometric
methods can continuously quantify collagen accumulation across
the full spectrum of disease with no upper limit.
To avoid the reliance on biopsy, non-invasive methods to
assess liver structure or function offer an obvious advantage
because of their markedly reduced risk and ability to acquire data
repeatedly over time. Among these, both transient- and magnetic14 vol. 60 j 905–906
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resonance-elastography (MRE) are methods that quantify tissue
stiffness as a reﬂection of ﬁbrosis content and/or inﬂammation
and edema. Hundreds of studies have evaluated these technolo-
gies, and the United States Food and Drug Administration
recently approved transient elastography for management of
patients with chronic viral hepatitis and fatty liver disease, in line
with the technology’s earlier widespread acceptance elsewhere in
the world. MRE offers the theoretical advantage over transient
elastography of sampling the entire liver rather than a small
region of interest. In the cross-sectional study of 430 patients
reported by Asrani et al., mean liver stiffness by MRE was signif-
icantly higher in those with decompensated liver disease than in
those who were compensated. More importantly, in 167 patients
from this study followed prospectively for a mean of 27 months,
those patients with a mean value of >5.8 kPa had an almost
ﬁve-fold hazard of decompensation.
How would one use this information to impact clinical deci-
sion-making or improve outcomes? At the least, accurate stratiﬁ-
cation of decompensation risk by MRE could be used to increase
the frequency of clinical follow-up, seek evidence of esophageal
varices, or avoid disease-speciﬁc therapies that might provoke
decompensation. In addition, MRE could help identify a subgroup
of patients at high risk who might beneﬁt most from effective
anti-ﬁbrotic therapies once they are available.
But the holy grail of non-invasive diagnostics is not simply to
predict risk of decompensation. Rather, an ideal diagnostic must
also correlate with improved outcomes following therapeutic
intervention in order to justify its use in place of biopsy in clinical
trials or practice. In addition to elastography, other methods
undergoing evaluation for this purpose include functional breath
or clearance tests [9,10], serum markers [11], hepatic venous
pressure gradient measurement [12], Doppler/ultrasound and
CT/MRI. Ultimately, a combination of tests may yield the greatest
precision in quantifying risk and documenting response to
therapy.
The prospect of effective therapies for both fatty liver disease
[13] and hepatic ﬁbrosis [14] has heightened the sense of urgency
in identifying non-invasive measures that correlate with clinical
outcomes. The importance of progress in addressing this chal-
lenge was evident in the jointly sponsored AASLD-FDA endpoints
conference held in September, 2013, to help clarify endpoints for
clinical trials that evaluate therapies for NAFLD (http://
www.aasld.org/additionalmeetings/Pages/aasldfdanash.aspx). A
written summary of the meeting recommendations is anticipated
soon. Together with studies like those of Tsochatzis et al. and
Asrani et al., these recommendations will help us replace a crystal
ball that prophesizes the prognosis of liver diseases with a calcu-
lator that can quantify its consequences.906 Journal of Hepatology 201Conﬂict of interest
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